NCT06277960Active, not recruiting
Septal Ablation for Obstructive HCM
A Prospective, Single-center, Single-arm Clinical Study to Evaluate the Safety and Effectiveness of Percutaneous Intramyocardial Septal Radiofrequency Ablation System in the Treatment of Hypertrophic Obstructive Cardiomyopathy
Source: ClinicalTrials.gov · Last updated 30 May 2025
Brief summary (registry, in English)
Hypertrophic cardiomyopathy (HCM) is a common clinical genetic-related disease, with a global incidence of 0.2%-0.5%, but only a few cases (10-20%) have been clinically diagnosed. About 70% of them are hypertrophic obstructive cardiomyopathy (HOCM), these HOCM patients have significant clinical symptoms, including progressively increasing fatigue, angina, exertional dyspnea, and syncope. Conservative medications are used to treat the vast majority of patients. Invasive therapy, which includes surgical myectomy, percutaneous transluminal septal myocardial ablation(PTSMA), percutaneous intramyocardial septal radiofrequency ablation (PIMSRA) and percutaneous endocardial septal radiofrequency ablation (PESA) is introduced to patients with refractory symptoms or drug resistance. However, surgical operations are complicated and high risk procedures with high mortality. Interventional approaches are very difficult to perform and therefore the application is limited. Previous researches have shown that interventricular septal radiofrequency ablation could effectively reduce the left ventricular outflow tract pressure gradient (LVOTG), thereby treating obstructive hypertrophic cardiomyopathy (HOCM). This device is based on the same radiofrequency ablation energy principle, however, the catheter is introduced into the right ventricle and performs ablation treatment on the hypertrophic interventricular septum, which is potentially a lower risk route of access for septal ablation than currently attempted interventional approaches. The purpose of this study is to evaluate the safety and efficacy of percutaneous intramyocardial septal ablation catheters in the treatment of obstructive hypertrophic cardiomyopathy.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 20 (actual)
- First submitted
- 27 Jan 2024
- Start date
- 28 Mar 2024
- Primary completion date
- 30 Dec 2025
- Lead sponsor
- SuZhou Sinus Medical Technologies Co.,Ltd
- Diseases
- Hypertrophic cardiomyopathy
- NCT number
- NCT06277960
What you commit to
- Study type: Interventional
- Participants enrolled: 20
- From 28 Mar 2024 to the primary completion date, 30 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Subject with Sudden Cardiac Death Index ≥ 10%.
- Subject combined with other heart diseases requires surgical treatment.
- Subject with heart failure(Defined as resting heart failure after intensive anti-heart failure therapy, left ventricular fraction of ejecting\< 40%).
Other
- Subject is pregnant, lactating, or planned to conceive during a clinical study.
- Subject with interventricular septal thickness ≥ 30mm.
- Subject has undergone other ventricular septal volume reduction surgeries.
- Subject with complete right bundle branch block on electrocardiogram.
- Subject is mentally incapacitated or unable to understand the study requirements.
- Subject has participated in other clinical trials within 3 months.
- The investigator determines that there is any situation that affects the safety of the subjects or interferes with the evaluation of test results.
Who the study is looking for
- 18 years old ≤ age ≤ 75 years old, no gender limit.
- Subject has pressure gradient of left ventricular outflow tract (LVOT) ≥50 mmHg（with Systolic Anterior Motion）in the resting-state or after exercise stress test.
- Subject with New York Heart Association (NYHA) cardiac function ≥ II grade.
- Subject with adequate drug treatment is not effective or cannot tolerate side effects of the drug.
- Subject was informed of the nature of the clinical study and agreed to participate in all the requirements of the clinical study, signed an ethics committee-approved informed consent form before conducting any special examinations and/or treatments related to the clinical study.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sir Run Run Shaw Hospital Coordinator of this site? Confirm its status | Hangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.